Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages
Maliheh Nazari-Jahantigh, … , Christian Weber, Andreas Schober
Maliheh Nazari-Jahantigh, … , Christian Weber, Andreas Schober
Published October 8, 2012
Citation Information: J Clin Invest. 2012;122(11):4190-4202. https://doi.org/10.1172/JCI61716.
View: Text | PDF
Research Article Cardiology

MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages

  • Text
  • PDF
Abstract

Macrophages in atherosclerotic plaques drive inflammatory responses, degrade lipoproteins, and phagocytose dead cells. MicroRNAs (miRs) control the differentiation and activity of macrophages by regulating the signaling of key transcription factors. However, the functional role of macrophage-related miRs in the immune response during atherogenesis is unknown. Here, we report that miR-155 is specifically expressed in atherosclerotic plaques and proinflammatory macrophages, where it was induced by treatment with mildly oxidized LDL (moxLDL) and IFN-γ. Leukocyte-specific Mir155 deficiency reduced plaque size and number of lesional macrophages after partial carotid ligation in atherosclerotic (Apoe–/–) mice. In macrophages stimulated with moxLDL/IFN-γ in vitro, and in lesional macrophages, loss of Mir155 reduced the expression of the chemokine CCL2, which promotes the recruitment of monocytes to atherosclerotic plaques. Additionally, we found that miR-155 directly repressed expression of BCL6, a transcription factor that attenuates proinflammatory NF-κB signaling. Silencing of Bcl6 in mice harboring Mir155–/– macrophages enhanced plaque formation and CCL2 expression. Taken together, these data demonstrated that miR-155 plays a key role in atherogenic programming of macrophages to sustain and enhance vascular inflammation.

Authors

Maliheh Nazari-Jahantigh, Yuanyuan Wei, Heidi Noels, Shamima Akhtar, Zhe Zhou, Rory R. Koenen, Kathrin Heyll, Felix Gremse, Fabian Kiessling, Jochen Grommes, Christian Weber, Andreas Schober

×

Figure 10

Role of BCL6 in miR-155–mediated atherosclerosis.

Options: View larger image (or click on image) Download as PowerPoint
Role of BCL6 in miR-155–mediated atherosclerosis.
Partially ligated caro...
Partially ligated carotid arteries from Apoe–/– mice harboring Mir155–/– BM were perivascularly treated with Bcl6 siRNA or nontargeting control siRNA. (A) Lesion area and medial area were determined in carotid artery sections stained with EVG by planimetry. Representative images are shown. (B) Number of macrophages in lesions from the carotid artery, analyzed by immunostaining for MAC2 (green). Representative images are shown, and the number of MAC2+ cells per lesion was determined. (C) Combined immunostaining for CCL2 (green) and MAC2 (red) was performed in carotid artery sections, and the percentage of CCL2+ macrophages (yellow) was quantified. n = 4–5 per group. *P < 0.05. Scale bars: 100 μm. Data are mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts